Bank of America Corp DE Increases Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

Bank of America Corp DE raised its holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 905.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 690,284 shares of the company's stock after acquiring an additional 621,614 shares during the period. Bank of America Corp DE owned 0.76% of Aquestive Therapeutics worth $2,457,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Price T Rowe Associates Inc. MD raised its holdings in Aquestive Therapeutics by 16.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,669 shares of the company's stock valued at $99,000 after acquiring an additional 3,821 shares during the last quarter. MetLife Investment Management LLC raised its holdings in Aquestive Therapeutics by 11.4% in the 4th quarter. MetLife Investment Management LLC now owns 40,221 shares of the company's stock valued at $143,000 after acquiring an additional 4,125 shares during the last quarter. Bank of Montreal Can raised its holdings in Aquestive Therapeutics by 10.1% in the 4th quarter. Bank of Montreal Can now owns 54,300 shares of the company's stock valued at $193,000 after acquiring an additional 4,999 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Aquestive Therapeutics by 3.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 210,669 shares of the company's stock valued at $750,000 after acquiring an additional 7,129 shares during the last quarter. Finally, SG Americas Securities LLC raised its holdings in Aquestive Therapeutics by 28.7% in the 4th quarter. SG Americas Securities LLC now owns 32,966 shares of the company's stock valued at $117,000 after acquiring an additional 7,347 shares during the last quarter. 32.45% of the stock is currently owned by institutional investors and hedge funds.

Aquestive Therapeutics Stock Up 4.7%

Shares of NASDAQ AQST traded up $0.16 during trading on Thursday, hitting $3.57. 2,089,693 shares of the company traded hands, compared to its average volume of 1,529,769. The company has a 50-day moving average price of $2.67 and a 200-day moving average price of $3.15. Aquestive Therapeutics, Inc. has a 1 year low of $2.12 and a 1 year high of $5.80. The firm has a market capitalization of $354.60 million, a P/E ratio of -7.93 and a beta of 2.02.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.07). The company had revenue of $8.72 million for the quarter, compared to analysts' expectations of $12.23 million. Research analysts predict that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Oppenheimer assumed coverage on Aquestive Therapeutics in a report on Monday. They issued an "outperform" rating and a $7.00 price target for the company. Alliance Global Partners reissued a "buy" rating on shares of Aquestive Therapeutics in a research note on Friday, March 7th. Raymond James set a $7.00 price objective on shares of Aquestive Therapeutics in a research note on Friday, March 7th. HC Wainwright reissued a "buy" rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a research note on Thursday, May 15th. Finally, Lake Street Capital lowered their price objective on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating for the company in a research note on Friday, March 7th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $10.14.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.